--- title: "Hepion Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286466673.md" datetime: "2026-05-14T20:50:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286466673.md) - [en](https://longbridge.com/en/news/286466673.md) - [zh-HK](https://longbridge.com/zh-HK/news/286466673.md) --- # Hepion Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.07. EBIT: As of FY2026 Q1, the actual value is USD -796.38 K. Hepion Pharmaceuticals, Inc. has strategically shifted its focus from drug therapy for chronic liver diseases to becoming a medical diagnostic company. #### Segment Revenue - Hepion Pharmaceuticals, Inc. reported no revenues for both the three months ended March 31, 2026, and March 31, 2025, as it has not commercialized any medical diagnostic products and does not anticipate doing so for several years. #### Operational Metrics - **Research and Development (R&D) Expenses**: R&D expenses increased to $70,000 for the three months ended March 31, 2026, compared to $22,235 for the same period in 2025, primarily due to the Cirna licensing agreement in 2026. - **General and Administrative (G&A) Expenses**: G&A expenses decreased by $0.5 million to $728,509 for the three months ended March 31, 2026, from $1,258,360 in the prior year period, mainly due to reductions in legal and accounting fees, insurance, and consulting services, partially offset by increased severance costs. - **Total Operating Expenses**: Total operating expenses decreased by $482,086 to $798,509 for the three months ended March 31, 2026, from $1,280,595 for the same period in 2025. - **Interest Expense, net**: Interest expense decreased to - $2,129 for the three months ended March 31, 2026, from - $24,811 for the same period in 2025. - **Change in Fair Value of Derivative Financial Instruments—Warrants**: This resulted in an expense of - $10,153 for the three months ended March 31, 2026, a significant reduction from - $4,800,481 for the same period in 2025. - **Net Loss**: The net loss significantly improved to - $810,791 for the three months ended March 31, 2026, compared to - $6,105,887 for the three months ended March 31, 2025. #### Cash Flow - **Operating Activities**: Net cash provided by operating activities was $578,584 for the three months ended March 31, 2026, primarily due to a $1.0 million refund from a prepaid insurance policy, partially offset by operating losses. In contrast, net cash used in operating activities was - $1,117,422 for the three months ended March 31, 2025. - **Investing Activities**: There was no cash provided by or used in investing activities during both periods. - **Financing Activities**: Net cash provided by financing activities was $195,934 for the three months ended March 31, 2026, which included a $250,000 cash receipt related to a stock subscription liability, partially offset by a - $54,066 payment on notes payable. For the same period in 2025, net cash provided by financing activities was $5,297,403, mainly from $8.2 million in net proceeds from warrant exercises and equity issuance, offset by a - $2.9 million payment on notes payable. #### Unique Metrics - **Cash Position**: As of March 31, 2026, Hepion Pharmaceuticals, Inc. had $2.6 million in cash. - **Working Capital**: Working capital was $2.0 million as of March 31, 2026, a decrease of $0.8 million from $2.8 million as of December 31, 2025, primarily due to operating costs. - **Accumulated Deficit**: From inception through March 31, 2026, the company had an accumulated deficit of - $246.9 million. - **Intellectual Property Acquisition**: An upfront payment of $50,000 and patent expenses totaling $70,000 were incurred for the intellectual property license agreement with Cirna Diagnostics, LLC, expensed as purchased in-process research and development. #### Future Outlook and Strategy - Hepion Pharmaceuticals, Inc.’s ability to continue operations is uncertain due to recurring losses and negative cash flows, necessitating additional financing. The company will require further capital to fund operations, and a failure to secure this could lead to delays, reductions, or termination of operations. The strategy involves continuing to expend substantial resources on research and development for acquired assets. While three products from the New Day licensing agreement have CE marks, the company cannot guarantee when or how much revenue these products will generate. ### Related Stocks - [HEPA.US](https://longbridge.com/en/quote/HEPA.US.md) ## Related News & Research - [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [Ealixir Reports First Quarter 2026 Results | EAXR Stock News](https://longbridge.com/en/news/287216349.md)